Complete Genomics is making headlines. Read the most recent news about Complete Genomics and advances in complete human genome sequencing.
BGI-Shenzhen (“BGI”), a leading international genomics organization based in Shenzhen, China, today announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has successfully completed the acquisition of Complete Genomics, Inc. (formerly NASDAQ: GNOM) ("Complete"), an innovative leader in accurate whole human genomic sequencing.
>> read moreBGI-Shenzhen ("BGI") and Complete Genomics, Inc. (Nasdaq: GNOM) ("Complete") announced today that they have obtained approval from the State Administration of Foreign Exchange of the People’s Republic of China regarding BGI’s proposed acquisition of Complete pursuant to the previously announced Agreement and Plan of Merger, dated as of September 15, 2012, among BGI, Beta Acquisition Corporation and Complete.
>> read moreBGI-Shenzhen ("BGI") and Complete Genomics, Inc. (Nasdaq: GNOM) ("Complete") announced today that they have obtained approval from the Ministry of Commerce of the People’s Republic of China regarding BGI’s proposed acquisition of Complete pursuant to the previously announced Agreement and Plan of Merger, dated as of September 15, 2012, among BGI, Beta Acquisition Corporation and Complete.
>> read moreBGI-Shenzhen ("BGI") and Complete Genomics, Inc. (Nasdaq: GNOM) ("Complete") announced today that they have obtained clearance from the National Development and Reform Commission of the People’s Republic of China regarding BGI’s proposed acquisition of Complete pursuant to the previously announced Agreement and Plan of Merger, dated as of September 15, 2012, among BGI, Beta Acquisition Corporation and Complete.
>> read moreBGI-Shenzhen (“BGI”) and Complete Genomics, Inc. (Nasdaq: GNOM) (“Complete”) announced today that they have received early termination of the Hart-Scott-Rodino waiting period from the Federal Trade Commission (“FTC”) regarding BGI’s proposed acquisition of Complete pursuant to the previously announced Agreement and Plan of Merger, dated as of September 15, 2012, among BGI, Beta Acquisition Corporation and Complete.
>> read moreBGI-Shenzhen ("BGI") and Complete Genomics, Inc. (Nasdaq: GNOM) ("Complete") announced today that they have obtained clearance from the Committee on Foreign Investment in the United States ("CFIUS") regarding BGI's proposed acquisition of Complete pursuant to the previously announced Agreement and Plan of Merger, dated as of September 15, 2012, among BGI, Beta Acquisition Corporation and Complete.
>> read moreComplete Genomics, Inc. (Nasdaq:GNOM), the whole human genome sequencing company, today announced financial results for its fiscal quarter ended September 30, 2012.
>> read moreComplete Genomics, Inc. (Nasdaq:GNOM) today announced that Magistrate Judge Elizabeth D. Laporte of the U.S. District Court for the Northern District of California issued an Order granting Complete's Motion for Partial Summary Judgment of invalidity in the patent infringement lawsuit filed against Complete by Illumina, Inc.
>> read moreMOUNTAIN VIEW, Calif. and SHENZHEN, China, Sept. 17, 2012 -- Complete Genomics, Inc. (Nasdaq:GNOM) ("Complete"), an innovative leader in whole human genomic sequencing, and BGI-Shenzhen ("BGI"), a leading international genomics company based in Shenzhen, China, today announced that they have entered into a definitive merger agreement. Through...
>> read moreComplete Genomics, Inc. (Nasdaq:GNOM), the whole human genome sequencing company, today announced financial results for its fiscal quarter ended June 30, 2012.
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM) today announced that its high-accuracy, whole-genome sequencing service has been used to study human evolution in three African populations. The findings, to be published online today, will be highlighted on the cover of the Aug. 3 issue of the journal Cell.
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM) and Ingenuity® Systems Inc. today announced that Complete Genomics will bundle the Ingenuity Variant Analysis application with its research whole genome sequencing services.
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM), announced today that its Long Fragment Read (LFR) technology for whole genome sequencing dramatically improves accuracy, enables fully-phased genomes, and significantly reduces the amount of DNA required for testing.
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM), announced today that it intends to vigorously defend itself against the patent infringement suit recently filed by Illumina, Inc. in the U.S. District Court for the Southern District of California.
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM), today announced that it is taking steps to reduce cash consumption and has engaged Jefferies & Company, Inc. to assist it in exploring strategic alternatives. The company also plans to focus on development of clinical applications for its whole human genome sequencing service, while continuing to provide high-quality genomes to research customers.
>> read moreComplete Genomics Inc. (NASDAQ: GNOM) announced today that it has sequenced the genomes of 600 individuals from 20 Mexican-American families from San Antonio in what is thought to be the largest whole genome sequencing family study conducted to date
>> read moreComplete Genomics Inc. (NASDAQ: GNOM), the whole human genome sequencing company, today announced that it has signed four new distributor agreements with well-established Asia-Pacific life sciences companies
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM) today announced financial results for its quarter ended March 31, 2012.
>> read more
Complete Genomics, Inc. (Nasdaq: GNOM) will release its first quarter 2012 financial results at approximately 1:00 p.m. PDT on May 7, 2012.
>> read moreComplete Genomics Inc. (NASDAQ: GNOM) has begun accepting DNA samples derived from human saliva.
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM), the whole human genome sequencing company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2011.
>> read moreComplete Genomics, Inc. (Nasdaq:GNOM) will release its fourth quarter and fiscal year 2011 financial results after markets close on March 8, 2012.
>> read moreComplete Genomics (NASDAQ: GNOM) today announced that members of its management team will present at the following conferences in March
>> read moreComplete Genomics Inc. (NASDAQ: GNOM), the whole human genome sequencing company, today announced the formation of its Genomic Medicine Advisory Board (GMAB).
>> read moreComplete Genomics, Inc. (NASDAQ: GNOM) announced today that the journal Nature has published a neuroblastoma study conducted using the company’s high-depth whole human genome sequencing service.
>> read moreComplete Genomics Inc. (NASDAQ: GNOM) announced today that Genome Research has published a paper it co-authored describing the effects of hepatitis B virus (HBV) integration into the genomes of liver cancer patients.
>> read moreComplete Genomics Inc. (NASDAQ: GNOM) today announced that the company will be included in MIT’s Technology Review TR50, an annual list of the 50 most innovative technology companies in the world. It is the third-consecutive year that Complete Genomics has been named to the list.
>> read moreComplete Genomics Inc. (NASDAQ: GNOM), the whole human genome sequencing company, today introduced its Genomic Discovery Software Partners Program.
>> read moreComplete Genomics Inc. (NASDAQ: GNOM) announced today that it has been selected by Mayo Clinic’s Center for Individualized Medicine to provide outsourced whole human genome sequencing. Mayo Clinic researchers will now be able to employ Complete Genomics’ sequencing service for some of its large-scale whole genome sequencing projects.
>> read moreComplete Genomics Inc. (NASDAQ: GNOM) announced today that the Journal of Computational Biology has published online the company’s paper describing some of the computational methods that enable it to produce highly-accurate whole human genome sequencing data.
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM), today announced that the company delivered approximately 3,000 genomes to its customers in 2011 and is entering 2012 with contracts for approximately 5,800 genomes.
>> read moreComplete Genomics (NASDAQ: GNOM) today announced that Ajay Bansal, Chief Financial Officer of Complete Genomics will present at the Oppenheimer 22nd Annual Healthcare Conference at 11:25 a.m. ET on Wednesday, December 14, 2011.
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM), the whole human genome sequencing company, today announced its financial results for the quarter ended September 30, 2011.
>> read moreComplete Genomics, Inc. (Nasdaq: GNOM) will release its third quarter 2011 financial results after markets close on November 7, 2011.
>> read moreComplete Genomics (NASDAQ: GNOM) today announced that Dr. Cliff Reid, chairman, president, and CEO of Complete Genomics will present at the following conferences in November
>> read moreComplete Genomics Inc. (NASDAQ: GNOM), the whole human genome sequencing company, introduced its new Cancer Sequencing Service today at the International Congress of Human Genetics (ICHG) and American Society of Human Genetics (ASHG) Annual Meeting in Montréal.
>> read moreComplete Genomics Inc. (NASDAQ: GNOM), the whole human genome sequencing company, and the not-for-profit Scripps Health system today announced a major collaboration that will help further the Wellderly Study, a landmark scientific research initiative aimed at unlocking the genetic secrets of lifelong health.
>> read moreMOUNTAIN VIEW, Calif., and FALLS CHURCH, Va. – Complete Genomics Inc. (NASDAQ: GNOM), a complete human genome sequencing company, and Inova Health System, a not-for-profit healthcare system based in Northern Virginia, today announced additional details about their partnership.
>> read moreComplete Genomics (NASDAQ: GNOM) today announced that members of its management team will present at the following conferences in September
>> read moreComplete Genomics Inc. (NASDAQ: GNOM), the complete human genome sequencing company, today announced it has appointed Keith Raffel as chief commercial officer (CCO) and Dr. Jill Hagenkord as chief medical officer (CMO).
>> read moreComplete Genomics Inc. (NASDAQ: GNOM), the complete human genome sequencing company, today announced additional details about the option that SAIC-Frederick Inc. has exercised to have Complete Genomics sequence the DNA from more than 500 pediatric cancer cases.
>> read more